Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/bimekizumab-demonstrates-sustained-improvements-severity-2026a10005qx?src=rss
Author :
Publish date : 2026-02-26 12:00:00
Copyright for syndicated content belongs to the linked Source.
